Founded in 2015, Airfinity was created to systematically capture and structure the new science disseminated at conferences, a valuable yet highly fragmented dataset. Through working with medical associations, research institutions and pharma companies, Airfinity learned that there were even bigger, more urgent questions that the industry as a whole was struggling to answer
This more ambitious purpose also had a personal angle; in 2018, Founder and CEO Rasmus Bech Hansen lost his mother to cancer after a 9-year battle during which he saw the desperate need for potential new treatments. In retrospect, Rasmus has said the experience instilled both him and the company with a stronger purpose; an urgency and realisation that better information can save lives.
When COVID-19 emerged in early 2020, we quickly saw that our proprietary technology and expertise perfectly positioned us to help the world better navigate an unprecedented situation. With an unified goal, and a number of sleepless months, the company built the world's first dedicated COVID-19 health analytics and intelligence platform, which quickly became the trusted source of decision makers around the world. In 2021 alone, our data was cited more than 20,000 times in global media, reaching over 100 billion people.
Airfinity’s data and forecasts have made a material difference to the global response to COVID-19; improving the global response to the pandemic and, ultimately, helping to save lives.
Multiple industries rely on global structured time series data sets and advanced forecasting, from weather, to transport, to financial markets. The life science industry is far behind and based on siloed, national and static disease data – often based on self-reporting.
However, the life science industry is undergoing a data transformation driven by more and better personal health data, lower cost of diagnostics, better global data coverage and a range of other factors. Our approach is to ingest and structure any data point that has signal value and integrate it into our disease models in as close to real time as possible.
We also partner with a range of organisations, such as hospitals, to get more 1st party data. Our data agnostic approach enables us to integrate and connect data across countries and data sources.
Airfinity provides scenario planning tools and forecasts that can be understood, relied upon and used for decision making across the life science ecosystem. We use a unique quant analytics approach, combining advanced meta science, statistics, epidemiology and machine learning solutions to dynamically understand true disease prevalence and underlying outcome drivers.
Airfinity has become the world's leading source of disease forecasting, specialising in infectious diseases, cardiovascular, metabolic, and renal diseases and other critical areas including RNA. For example, ask us about the potential impact of a vaccine or treatment on hospitalisations, the impact of a new variant or strain on candidate effectiveness, or what different uptake scenarios will mean for the burden of disease.
Airfinity aims for the highest standards and quality, and at the same time operates at speed - clients get answers in hours, not months, so that we can be relied upon by the decision makers who know that the cost of failure is the cost of lives.